Merck & Co.
AWARDS
NEWS
The FDA said that it is not authorizing molnupiravir’s use during pregnancy as there are hardly any clinical scenarios where the benefits appear to outweigh the risks.
Novartis has grown weary of waiting, dropping out of its deal to fund Mesoblast’s floundering COVID-19 treatment.
As of now, six studies related to islatravir are on full clinical hold, while seven are on partial clinical hold. Here are more updates on the development of this drug.
The 2021 San Antonio Breast Cancer Symposium is meeting December 7–10 at the Henry B. Gonzalez Convention Center in San Antonio, Texas, and virtually.
The news comes just three weeks after Merck paused its Phase II IMAGINE-DR trial, which was studying a combination of islatravir with MK-8507.
LAG-3 is a priority focus in cancer immunotherapy because its inhibition has the potential to make PD-1 inhibitors work in more patients.
JOBS
IN THE PRESS